2. Search Result
Search Result
Results for "

ethanolamides

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

10

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112528
    Glycerophospho-N-palmitoyl ethanolamine

    GP-NPEA

    		 Others Metabolic Disease
    Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .
    Glycerophospho-N-palmitoyl ethanolamine
  • HY-157829
    (R)-Palmitoyl-(2-methyl)ethanolamide

    Me-PEA

    		 Endogenous Metabolite Cancer
    (R)-Palmitoyl-(2-methyl)ethanolamide (Me-PEA) is a competitive inhibitor of [3 H]-AEA metabolism with a Ki value of 6.6 μM .
    (R)-Palmitoyl-(2-methyl)ethanolamide
  • HY-113264S
    PGD2 ethanolamide-d4

    		Isotope-Labeled Compounds Others
    PGD2 ethanolamide-d4 is the deuterium labeled PGD2 ethanolamide[1].
    PGD2 ethanolamide-d4
  • HY-131651
    Leukotriene B4 ethanolamide

    LTB4 ethanolamide

    		 Endogenous Metabolite Leukotriene Receptor Cancer
    Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .
    Leukotriene B4 ethanolamide
  • HY-145475
    Nervonoyl ethanolamide

    NEA

    		 Others Neurological Disease Inflammation/Immunology
    Nervonoyl ethanolamide (NEA) is an endogenous cannabinoid that can act as a presynaptic and postsynaptic neuromodulator. Nervonoyl ethanolamide can also be used in the research of inflammation .
    Nervonoyl ethanolamide
  • HY-157833
    Heptadecanoyl ethanolamide

    		Cannabinoid Receptor Metabolic Disease
    Heptadecanoyl ethanolamide is an endogenous cannabinoid. Heptadecanoyl ethanolamide is a synthetic analog of PEA which incorporates an odd-numbered (17-carbon) fatty acid chain .
    Heptadecanoyl ethanolamide
  • HY-W721596
    Pentadecanoyl ethanolamide

    		Endogenous Metabolite Neurological Disease
    Pentadecanoyl ethanolamide is derivate of endougenous lipid amides, the N-acylethanolamines. Pentadecanoyl ethanolamide exhibits anticonvulsant efficacy in electroshocked mice without significant toxicity .
    Pentadecanoyl ethanolamide
  • HY-165082
    Tricosanoyl ethanolamide

    N-(2-Hydroxyethyl)-tricosanamide

    		 Others Neurological Disease
    Tricosanoyl ethanolamide is a member of endocannabinoids and its structure consists of ethanolamine and tricosanoic acid, which contains 23 carbon atoms. Tricosanoyl ethanolamide can be used for research of diseases related to the endocannabinoid system .
    Tricosanoyl ethanolamide
  • HY-130660
    Prostaglandin F2α ethanolamide

    Prostamide F2α

    		 Prostaglandin Receptor Endocrinology
    Prostaglandin F2α ethanolamide (Prostamide F2α) is an ethanolamide-like G protein-coupled receptor. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord .
    Prostaglandin F2α ethanolamide
  • HY-119723
    Myristoyl ethanolamide

    N-Myristoylethanolamine

    		 Others Others
    Myristoyl ethanolamide (N-Myristoylethanolamine) is a class of N-acylserinol compounds .
    Myristoyl ethanolamide
  • HY-127061
    Palmitoleoyl ethanolamide

    POEA

    		 Others Others
    Palmitoleoyl ethanolamide (POEA) is an endogenous fatty amide with biological activity .
    Palmitoleoyl ethanolamide
  • HY-120968
    Arachidoyl ethanolamide

    N-(2-Hydroxyethyl)-eicosanamide

    		 Others Metabolic Disease
    Arachidoyl Ethanolamide (N-(2-hydroxyethyl)-eicosanamide) is an ester product.
    Arachidoyl ethanolamide
  • HY-120969
    Docosanoyl ethanolamide

    N-(2-Hydroxyethyl)-docosanamide

    		 Others Metabolic Disease
    Docosanoyl Ethanolamide (N-(2-hydroxyethyl)-docosanamide) is an ester product.
    Docosanoyl ethanolamide
  • HY-166206
    (9Z,11E)-Octadecadien ethanolamide

    		Others Metabolic Disease
    (9Z,11E)-Octadecadien ethanolamide is an ester product.
    (9Z,11E)-Octadecadien ethanolamide
  • HY-121996
    Prostaglandin E2 Ethanolamide

    PGE2 ethanolamide

    		 Prostaglandin Receptor COX Inflammation/Immunology
    Prostaglandin E2 Ethanolamide (PGE2-EA), an analog of PGE2, can be formed enzymatically following COX-2 oxygenation of endocannabinoids. Prostaglandin E2 Ethanolamide (PGE2-EA) could modulate the production of the proinflammatory cytokine TNF-α in human blood and human monocytic cells .
    Prostaglandin E2 Ethanolamide
  • HY-113264
    PGD2 ethanolamide

    		Apoptosis Cancer
    PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .
    PGD2 ethanolamide
  • HY-W747573
    N-Linolenoylethanolamine

    18:3 NAE; α-Linolenoyl ethanolamide

    		 TRP Channel Neurological Disease
    N-Linolenoylethanolamine (18:3 NAE) is an endocannabinoid. N-Linolenoylethanolamine is a vanillin receptor (TRPV1) agonist .
    N-Linolenoylethanolamine
  • HY-19636A
    JNJ-42165279 dihydrochloride

    		FAAH Others
    JNJ-42165279 (dihydrochloride) is aFAAHinhibitor with IC50 of 70 nM and 313 nM for hFAAH and rFAAH, respectively .
    JNJ-42165279 dihydrochloride
  • HY-165081
    Docosaenoyl ethanolamide

    N-(2-Hydroxyethyl)-13Z-docosenamide

    		 Others Others
    Docosaenoyl ethanolamide (N-(2-Hydroxyethyl)-13Z-docosenamide) is one of a fatty N-acyl ethanolamines. Ethanolamines can be detected at relatively high levels in rat cerebrospinal fluid .
    Docosaenoyl ethanolamide
  • HY-118816
    11β-Prostaglandin F2α

    11-epi PGF2α-EA; 11β-PGF2α-EA; 11β-Prostamide F2α

    		 Others Metabolic Disease
    11β-Prostaglandin F2α ethanolamide (11β-PGF2α-EA) is the theoretical hepatic metabolite of PGD2-EA, produced during COX-2 metabolism of the endogenous cannabinoid AEA which is found in brain, liver, and other mammalian tissues.1 AEA can be used directly by COX-2 and specific PG synthase to produce ethanolamide congeners of the classical PGs. PGD2-EA is formed in activated RAW 264.7 cells treated with AEA.
    11β-Prostaglandin F2α
  • HY-137567
    Prostaglandin E1 ethanolamide

    		Prostaglandin Receptor Cancer
    Prostaglandin E1 ethanolamide is an analog of prostaglandin E1 (PGE1) and may effectively inhibit GLI2-induced expression of target genes, including Gli1 and Ptch1, and tumor growth .
    Prostaglandin E1 ethanolamide
  • HY-115358
    Lignoceroyl Ethanolamide

    Tetracosanoic acid monoethanolamide

    		 Endogenous Metabolite Metabolic Disease
    Lignoceroyl ethanolamide is a member of the family of fatty N-acyl ethanolamines collectively called endocannabinoids. Whereas lignoceric acid has been detected at relatively high levels in rat cerebrospinal fluid, the specific role and relative importance of its ethanolamine metabolite have not been determined.
    Lignoceroyl Ethanolamide
  • HY-139247
    pNPS-DHA

    		Others Inflammation/Immunology
    pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC50 of 15 μM .
    pNPS-DHA
  • HY-P4154
    Bevonescein

    ALM-488

    		 Fluorescent Dye Neurological Disease
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-112747
    Soy PE

    LPI; PE (soy)

    		 Phospholipase Infection
    Phosphatidylethanolamine is the most abundant phospholipid in prokaryotes and the second most abundant found in the membrane of mammalian, plant, and yeast cells, comprising approximately 25% of total mammalian phospholipids. In the brain, phosphatidylethanolamine comprises almost half of the total phospholipids. It is synthesized mainly through the cytidine diphosphate-ethanolamine and phosphatidylserine decarboxylation pathways, which occur in the endoplasmic reticulum (ER) and mitochondrial membranes, respectively. It is a precursor in the synthesis of phosphatidylcholine and arachidonoyl ethanolamide and is a source of ethanolamine used in various cellular functions. In E. coli, phosphatidylethanolamine deficiency prevents proper assembly of lactose permease, suggesting a role as a lipid chaperone. It is a cofactor in the propagation of prions in vitro and can convert recombinant mammalian proteins into infectious molecules even in the absence of RNA. This product contains phosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 and sn-2 positions.
    Soy PE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: